Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years

Multiple Sclerosis

Volumn 20, Issue 10, 2014, Pages 1348-1354

  Schlaeger, Regina ^a   Schindler, Christian ^b,c   Grize, Leticia ^b,c   Dellas, Sophie ^a   Radue, Ernst W ^a   Kappos, Ludwig ^a,c   Fuhr, Peter ^a,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Evoked potentials; Magnetic resonance imaging; Multiple sclerosis; Prognosis

Indexed keywords

GADOLINIUM; CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ADULT; ARTICLE; BRAIN RADIOGRAPHY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DETERIORATION; DISABILITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EVOKED MUSCLE RESPONSE; EVOKED VISUAL RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LATENT PERIOD; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REPEAT PROCEDURE; AREA UNDER THE CURVE; DIAGNOSTIC USE; DISEASE COURSE; ELECTROENCEPHALOGRAPHY; ELECTROSTIMULATION; MULTIVARIATE ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHOTOSTIMULATION; REACTION TIME; TIME;

ADULT; AREA UNDER CURVE; CONTRAST MEDIA; DISABILITY EVALUATION; DISEASE PROGRESSION; ELECTRIC STIMULATION; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, MOTOR; EVOKED POTENTIALS, VISUAL; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; PHOTIC STIMULATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REACTION TIME; ROC CURVE; TIME FACTORS;

EID: 84941625935     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514525867     Document Type: Article

References (39)

1. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. Ann Neurol 2004; 56: 303-306.
2. Sayao AL, Devonshire V and Tremlett H. Longitudinal follow-up of 'benign' multiple sclerosis at 20 years. Neurology 2007; 68: 496-500.
3. Costelloe L, Thompson A, Walsh C, et al. Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry 2008; 79: 1245-1248.
4. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.
5. Runmarker B, Andersson C, Odén A, et al. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol 1994; 241: 597-604.
6. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-1438.
7. Confavreux C, Vukusic S and Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain 2003; 126: 770-782.
8. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998; 121: 495-503.
9. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-817.
10. Rovaris M, Confavreux C, Furlan R, et al. Secondary progressive multiple sclerosis: Current knowledge and future challenges. Lancet Neurol 2006; 5: 343-354.
11. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis. Gadolinium MRI Metaanalysis Group. Lancet 1999; 353: 964-969.
12. Izquierdo G, Angulo S, Garcia-Moreno JM, et al. Intrathecal IgG synthesis: Marker of progression in multiple sclerosis patients. Acta Neurol Scand 2002; 105: 158-163.
13. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349: 139-145.
14. Lalive PH, Menge T, Delarasse C, et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 2280-2285.
15. Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007; 356: 371-378.
16. Brettschneider J, Czerwoniak A, Senel M, et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One 2010; 5: e11986.
17. Simpson S Jr, Taylor B, Dwyer DE, et al. Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis. Mult Scler 2012; 18: 799-806.
18. Teunissen CE, Sombekke M, van Winsen L, et al. Increased plasma 8,12-iso-iPF2alpha-VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. Mult Scler 2012; 18: 1092-1098.
19. Freedman MS, Metzig C, Kappos L, et al. Predictive nature of IgM anti-?-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: A BENEFIT study analysis. Mult Scler 2012; 18: 966-973.
20. Leocani L, Rovaris M, Boneschi FM, et al. Multimodal evoked potentials to assess the evolution of multiple sclerosis: A longitudinal study. J Neurol Neurosurg Psychiatry 2006; 77: 1030-1035.
21. Kallmann BA, Fackelmann S, Toyka KV, et al. Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler 2006; 12: 58-65.
22. Invernizzi P, Bertolasi L, Bianchi MR, et al. Prognostic value of multimodal evoked potentials in multiple sclerosis: The EP score. J Neurol 2011; 258: 1933-1939.
23. Fuhr P, Borggrefe-Chappuis A, Schindler C, et al. Visual and motor evoked potentials in the course of multiple sclerosis. Brain 2001; 124: 2162-2168.
24. Jung P, Beyerle A and Ziemann U. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis. Mult Scler 2008; 14: 553-556.
25. Schlaeger R, D'Souza M, Schindler C, et al. Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. Clin Neurophysiol 2012; 123: 406-410.
26. Schlaeger R, D'Souza M, Schindler C, et al. Prediction of long-term disability in multiple sclerosis. Mult Scler 2012; 18: 31-38.
27. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
28. Kappos L, Lechner-Scott J and Wu S. Neurostatus.net: Independent internet platform for training and certification of physicians participating in projects that use a standardised, quantified neurological examination and assessment of Kurtzke's Functional Systems and Expanded Disability Status Scale in Multiple Sclerosis, http://www.neurostatus. net. (2007, accessed 4 July 2013).
29. Lechner-Scott J, Kappos L, Hofman M, et al. Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler 2003; 9: 154-159.
30. Stoehr M. Somatosensible Reizantworten von Nerven, Rückenmark und Gehirn. In: Stoehr M, Dichgans J, Buettner UW and Hess CW (eds) Evozierte potentiale. 3rd ed. Heidelberg: Springer Verlag, 1996, pp.72, 625-627.
31. Margaritella N, Mendozzi L, Garegnani M, et al. Sensory evoked potentials to predict short-term progression of disability in multiple sclerosis. Neurol Sci 2012; 33: 887-892.
32. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFN beta-1b trial. Neurology 2012; 78: 1315-1322.
33. Vucic S. The re-emergence of evoked potentials in multiple sclerosis: From diagnosis to prognostication. Clin Neurophysiol 2012; 123: 221-222.
34. Onofrj M, Gambi D, Bazzano S, et al. Evoked potentials (EPs) in experimental allergic encephalomyelitis: A study of EP modifications during the course of a controlled disease. Electromyogr Clin Neurophysiol 1992; 32: 125-135.
35. Mazón Peláez I, Vogler S, Strauss U, et al. Identification of quantitative trait loci controlling cortical motor evoked potentials in experimental autoimmune encephalomyelitis: Correlation with incidence, onset and severity of disease. Hum Mol Genet 2005; 14: 1977-1989.
36. Amadio S, Pluchino S, Brini E, et al. Motor evoked potentials in a mouse model of chronic multiple sclerosis. Muscle Nerve 2006; 33: 265-273.
37. Pelayo R, Montalban X, Minoves T, et al. Do multimodal evoked potentials add information to MRI in clinically isolated syndromes? Mult Scler 2010; 16: 55-61.
38. Pallix-Guyot M, Guennoc AM, Blasco H, et al. Predictive value of motor evoked potentials in clinically isolated syndrome. Acta Neurol Scand 2011; 124: 410-416.
39. Margaritella N, Mendozzi L, Garegnani M, et al. Exploring the predictive value of the evoked potentials score in MS within an appropriate patient population: A hint for an early identification of benign MS? BMC Neurol 2012; 12: 80.